Study Comparing Therapy for Advanced Relapsed/Refractory Multiple Myeloma With and Without Dexamethasone

PHASE3RecruitingINTERVENTIONAL
Enrollment

318

Participants

Timeline

Start Date

December 12, 2024

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2028

Conditions
Multiple MyelomaRelapse Multiple Myeloma
Interventions
DRUG

Dexamethasone

"ICARIA schema :~40mg (20mg for ≥75yr) on day 1, 8, 15, 22 of each cycle plus~IKEMA schema :~20 mg on day 1-2, day 8-9, day 15-16 and day 22-23 of each cycle~For subjects older than 75 years or underweight (BMI \<18.5), the dexamethasone dose may be administered at a total dose of 20 mg weekly.~In both schema (ICARIA or IKEMA), dexamethasone will be administrated up to 2 cycle (Arm 1) or until disease progression (Arm2)"

Trial Locations (1)

75012

RECRUITING

Service d'hématologie clinique et thérapie cellulaire, Saint-Antoine Hospital, Paris

All Listed Sponsors
lead

Assistance Publique - Hôpitaux de Paris

OTHER